Palisade misses topline for lead asset in Phase 2

  Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery

 Palisade Bio (Nasdaq: PALI), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today reported that the Company’s U.S. Phase 2 PROFILE study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection did not achieve its primary endpoint.

“First and foremost, I would like to extend our appreciation to all of the study participants, the clinical staff at the study sites, as well as our team. The PROFILE study has provided us with a definitive outcome and enabled us to quickly make the decision to no longer pursue the adhesions indication,” commented J.D. Finley, Chief Executive Officer of Palisade Bio.

https://finance.yahoo.com/news/palisade-bio-announces-topline-results-120500677.html